Takeda files NDA for alogliptin/metformin combo in the US
This article was originally published in Scrip
Executive Summary
Takeda has submitted a new drug application (NDA) for marketing approval of a fixed-dose combination alogliptin/metformin for type 2 diabetes to the US FDA, the company’s partner, Furiex Pharmaceuticals has confirmed.